Stay updated on Switchover Trial Imiglucerase to Plant Cell Express Clinical Trial
Sign up to get notified when there's something new on the Switchover Trial Imiglucerase to Plant Cell Express Clinical Trial page.

Latest updates to the Switchover Trial Imiglucerase to Plant Cell Express Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.4.3 has been added and the previous Revision: v3.4.2 entry has been removed.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2 and removed the funding-status notice (Revision: v3.4.1); these are administrative site updates. No study content or user functionality is affected; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedA site-wide status notice was added and the page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check48 days agoChange DetectedGlossary display was added, and a new label 'Last Update Submitted that Met QC Criteria' appears. Footer text and the page version reference were updated to 'No FEAR Act Data' and 'Revision: v3.4.0', replacing the previous 'No FEAR Act data' and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page revision was updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedUpdated the Study Details page’s Locations section to include new site entries (Florida, Georgia, New York, Victoria, Ontario) and revised the page to version 3.3.3. The previous HHS Vulnerability Disclosure link and revision 3.3.2 were removed.SummaryDifference0.7%

Stay in the know with updates to Switchover Trial Imiglucerase to Plant Cell Express Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Switchover Trial Imiglucerase to Plant Cell Express Clinical Trial page.